Investigating the prevalence of metabolic associated fatty liver disease in patients with type 2 diabetes in Jiangsu Province, China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prevalence and clinical characteristics of metabolic associated fatty liver disease (MAFLD) in patients diagnosed with type 2 diabetes mellitus (T2DM) in Jiangsu Province, China. It will utilize ultrasound attenuation parameters to non-invasively evaluate liver fat content and its correlation with insulin resistance. The study will involve measuring fasting blood glucose and insulin levels to better understand the relationship between T2DM and MAFLD. By identifying these correlations, the study seeks to enhance the understanding of how these conditions interact and affect patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
* UAP were measured based on iLivTouch
* Willing to attend this study and able to provide the written informed consent.

Exclusion Criteria:

* Other types of diabetes
* Patients unable to receive regular follow-up

Where it's running

• Zhongda Hospital, Medical School, Southeast University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Ling Li, Professor — Zhongda Hospital
• Study coordinator: Ling Li, Professor
• Email: lingli2022@hotmail.com
• Phone: +8613951606816

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glucagon resistance in MASLD and type 2 diabetes

  This will see if people with type 2 diabetes, with or without MASLD, respond differently to glucagon in liver fat oxidation and VLDL-triglyceride secretion.

  Recruiting University of Aarhus · Aarhus · NCT07246421

• Rifaximin treatment for metabolic-associated fatty liver disease

  This trial tests whether taking oral rifaximin for 24 weeks helps adults with metabolic-associated fatty liver disease (MAFLD) and is safe.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07185932

• New MRI methods to measure metabolism and predict outcomes in metabolic-associated fatty liver disease

  This project tests whether new MRI techniques can measure body metabolism and help predict disease status and prognosis for people with metabolic-associated fatty liver disease.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07149571

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Effects of a Low Valine Diet on Weight and Metabolism

  This study is testing if meal replacements with less valine can help overweight and obese people lose weight and improve their metabolism compared to regular meal replacements.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06883578

• Understanding Metabolic Associated Fatty Liver Disease in China

  This study is trying to learn more about metabolic liver disease in China by collecting health information and samples from patients to find markers that could help predict how the disease affects them.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT04573283

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.